Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D, Notni J, Buckle T, Van Oosterom MN, Steiger K, Ntziachristos V, Schwaiger M, Van Leeuwen FWB, Wester HJ (2019)
Publication Type: Journal article
Publication year: 2019
Book Volume: 60
Pages Range: 71-78
Journal Issue: 1
DOI: 10.2967/jnumed.118.212720
The prostate-specific membrane antigen (PSMA)-targeted radiotracers 68 Ga/ 177 Lu-PSMA-I&T and 99m Tc-PSMA-I&S (for imaging and surgery) are currently successfully used for clinical PET imaging, radionuclide therapy, and radioguided surgery of metastatic prostate cancer. To additionally exploit the high sensitivity and spatial resolution of fluorescence imaging for improved surgical guidance, a PSMA-I&T-based hybrid tracer, PSMA-I&F (DOTAGA-k(Sulfo-Cy5)-y-nal-k-Sub-KuE), has been developed and evaluated. Methods: The in vitro PSMA-targeting efficiency of PSMA-I&F, the reference PSMA-I&T, and their corresponding nat Ga-/ 68 Ga- and nat Lu/ 177 Lu counterparts was determined in LNCaP cells via competitive binding assays (IC
APA:
Schottelius, M., Wurzer, A., Wissmiller, K., Beck, R., Koch, M., Gorpas, D.,... Wester, H.-J. (2019). Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer. Journal of Nuclear Medicine, 60(1), 71-78. https://doi.org/10.2967/jnumed.118.212720
MLA:
Schottelius, Margret, et al. "Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer." Journal of Nuclear Medicine 60.1 (2019): 71-78.
BibTeX: Download